CR11107A - INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1 - Google Patents

INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1

Info

Publication number
CR11107A
CR11107A CR11107A CR11107A CR11107A CR 11107 A CR11107 A CR 11107A CR 11107 A CR11107 A CR 11107A CR 11107 A CR11107 A CR 11107A CR 11107 A CR11107 A CR 11107A
Authority
CR
Costa Rica
Prior art keywords
mcl
inhibitors
indoles
replaced
indoles replaced
Prior art date
Application number
CR11107A
Other languages
English (en)
Inventor
Steven W Elmore
Andrew J Souers
Xiaohong Song
Xilu Wang
Lisa A Hasvold
Le Wang
Aaron R Kunzer
Cheol-Min Park
Michael D Wendt
Zhi-Fu Tao
David Madar
Milan Bruncko
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR11107A publication Critical patent/CR11107A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos que inhiben la actividad de la proteina antiapoptotica Mcl-1, composiciones que contienen los compuestos, y metodos para tratar enfermedades relacionadas con la sobreexpresion o falta de regulacion de la proteina Mcl-1.
CR11107A 2007-04-16 2009-11-10 INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1 CR11107A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91203807P 2007-04-16 2007-04-16
US94965007P 2007-07-13 2007-07-13

Publications (1)

Publication Number Publication Date
CR11107A true CR11107A (es) 2010-02-09

Family

ID=39791546

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11107A CR11107A (es) 2007-04-16 2009-11-10 INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1

Country Status (18)

Country Link
US (3) US8445679B2 (es)
EP (2) EP3243814B1 (es)
JP (2) JP5496877B2 (es)
KR (1) KR101511074B1 (es)
CN (1) CN101743224A (es)
AU (1) AU2008242983B2 (es)
BR (1) BRPI0810365A2 (es)
CA (1) CA2682356C (es)
CO (1) CO6220947A2 (es)
CR (1) CR11107A (es)
DO (1) DOP2009000246A (es)
ES (2) ES2643164T3 (es)
IL (1) IL201432A0 (es)
MX (1) MX2009011211A (es)
MY (1) MY162157A (es)
NZ (1) NZ579833A (es)
WO (1) WO2008131000A2 (es)
ZA (1) ZA200906956B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Ｍｃｌ-1 억제제
MX2009011210A (es) * 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
WO2009143578A1 (en) * 2008-05-28 2009-12-03 The Council Of The Queensland Institute Of Medical Research Cancer drug target and methods of diagnosis and therapy
EP2376085B1 (en) 2008-12-19 2014-02-26 Genentech, Inc. Compounds and methods of use
KR101685718B1 (ko) * 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
US20130035304A1 (en) * 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
ES2659763T3 (es) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
EP2831067B1 (en) * 2012-03-29 2017-11-01 The Regents Of The University Of Michigan Small molecule inhibitors of mcl-1 and uses thereof
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
WO2014143659A1 (en) * 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
WO2014179734A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of Michigan Deuterated amlexanox
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
WO2015031608A1 (en) 2013-08-28 2015-03-05 Vanderbilt University Substituted indole mcl-1 inhibitors
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
US10533010B2 (en) 2014-03-27 2020-01-14 Vanderbilt University Substituted indole Mcl-1 inhibitors
WO2015153959A2 (en) 2014-04-04 2015-10-08 The Regents Of The University Of Michigan Small molecule inhibitors of mcl-1 and uses thereof
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
EP3212202B1 (en) 2014-10-29 2020-05-06 The Walter and Eliza Hall Institute of Medical Research Mcl-1 inhibitors for use in treating diseases caused by pathological neovascularisation
CN104557665B (zh) * 2015-01-09 2016-11-30 华东师范大学 光学活性3-取代吲哚衍生物及其合成方法和应用
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2856880T3 (es) 2015-04-15 2021-09-28 Araxes Pharma Llc Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
IL259051B2 (en) * 2015-11-02 2024-11-01 Carmel Haifa Univ Economic Corporation Ltd Compounds that mimic APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS), preparations containing them, methods and their uses in initiating differentiation and/or apoptosis in pre-malignant and malignant cells, and restoring their normal-like phenotype
KR102932353B1 (ko) 2015-11-16 2026-02-27 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017132538A1 (en) 2016-01-29 2017-08-03 The Regents Of The University Of Michigan Amlexanox analogs
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
JP7086395B2 (ja) 2016-03-04 2022-06-20 ヴァンダービルト ユニバーシティー 置換インドールＭｃｌ－１阻害剤
KR101885084B1 (ko) 2016-03-24 2018-08-03 기초과학연구원 N-아실 인돌 유도체의 아민화 방법
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CR20180499A (es) 2016-04-22 2019-01-25 Astrazeneca Ab Inhibidores de mcl1 macrocicliclos para tratar el cancer
EP3458459B1 (en) * 2016-05-19 2022-04-27 Bayer Aktiengesellschaft Macrocyclic indole derivatives
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
ES3036998T3 (en) 2017-08-18 2025-09-26 Amgen Inc Compounds that inhibit mcl-1 protein
MA50033A (fr) 2017-08-29 2020-07-08 Amgen Inc Composés macrocycliques permettant d'inhiber la protéine mcl-1
EP3710449B1 (en) 2017-11-17 2022-07-06 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
EP3710451A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Substituted macrocyclic indole derivatives
WO2019096914A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
EP3710456B1 (en) 2017-11-17 2022-09-21 The Broad Institute, Inc. Macrocyclic indole derivatives
AR113887A1 (es) 2017-11-17 2020-06-24 Bayer Ag Derivados de indol macrocíclicos sustituidos con cloro
EP3762393B1 (en) 2018-03-05 2023-01-11 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
WO2020063792A1 (zh) * 2018-09-30 2020-04-02 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
WO2020151738A1 (en) * 2019-01-23 2020-07-30 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrrazoles as mcl-1 inhibitors
WO2020221272A1 (zh) * 2019-04-30 2020-11-05 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
EP3969457B1 (en) 2019-05-17 2025-08-13 The Broad Institute Inc. Methods of preparing macrocyclic indoles
EP4010328A1 (en) * 2019-08-06 2022-06-15 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists
US20230021562A1 (en) 2019-11-21 2023-01-26 Janssen Pharmaceutica Nv Macrocylic indole derivatives mcl-1 inhibitors
CA3157590A1 (en) 2019-11-21 2021-05-27 Janssen Pharmaceutica Nv Macrocyclic sulfonyl derivatives as mcl-1 inhibitors
CN112898224B (zh) * 2019-12-04 2023-02-17 中国科学院上海药物研究所 一种烯丙基醇支撑的大环内酯化合物及其用途
TWI827924B (zh) 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
EP4157852A1 (en) 2020-05-29 2023-04-05 JANSSEN Pharmaceutica NV Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1
CA3181816A1 (en) * 2020-06-19 2021-12-23 Aldo Peschiulli N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
CN115943147A (zh) 2020-06-19 2023-04-07 詹森药业有限公司 N-连接的大环7-(吡唑-5-基)-吲哚衍生物作为mcl-1抑制剂
WO2022255888A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
JP2025540970A (ja) * 2022-12-06 2025-12-17 キャプター セラピューティクス エス．エー． ユビキチンリガーゼ及びターゲットｍｃｌ－１タンパク質に結合する二機能性化合物を使用するターゲティングされたタンパク質分解

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB888426A (en) * 1957-08-02 1962-01-31 Lab Francais Chimiotherapie Tryptamine-2-carboxylic acid derivatives and their preparation
US3303195A (en) * 1957-10-31 1967-02-07 Roussel Uclaf Methylated deserpidine
US3578669A (en) * 1969-09-16 1971-05-11 Sterling Drug Inc 1-((2 - substituted - 3 - indolyl) - lower-alkanoyl) - cycloalkyl - lower-alkylpiperidines and 1 - ((2 - hydroxymethyl-3 - indolyl)-lower-alkayl)-cycloalkyl-lower-alkylpiperidines
AR205437A1 (es) * 1972-09-25 1976-05-07 Hoffmann La Roche Procedimiento para la preparacion de derivados de indoloquinolinona
US4014883A (en) 1973-09-10 1977-03-29 Hoffmann-La Roche Inc. Indoloquinolines, intermediates and processes
CA1299174C (en) 1987-02-02 1992-04-21 Michael Edward Flaugh Alkylmelatonins
CS270491B1 (cs) * 1988-10-20 1990-06-13 Magdalena Ing Stankova Způsob výroby kyseliny 7-ethyl-2-karboxyindol- -3—yloclové
FR2662713B1 (fr) 1990-05-29 1994-04-08 Oreal Procede de teinture de fibres keratiniques avec un aminoindole associe a un derive quinonique.
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
RU2121997C1 (ru) * 1993-09-10 1998-11-20 Эйсай Ко., ЛТД Производные 7-амино-1н-индола
EP0791582A4 (en) 1995-08-04 1997-12-10 Otsuka Kagaku Kk DERIVATIVES OF INDOLE-2-CARBOXYLIC ACID ESTERS, AND BACTERICIDES FOR AGRICULTURE AND HORTICULTURE CONTAINING THEM AS ACTIVE INGREDIENTS
US6077812A (en) * 1997-02-26 2000-06-20 Fmc Corporation Cycloimido-substituted benzofused heterocyclic herbicides
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
CO4970713A1 (es) * 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
WO2002010169A1 (en) 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
IL154981A0 (en) * 2000-10-10 2003-10-31 Smithkline Beecham Corp Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
JP2007516203A (ja) * 2003-07-09 2007-06-21 バイオリポックス エービー 炎症の治療に有用なインドール類
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
ES2421139T3 (es) * 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
DK1663242T3 (da) * 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
AU2006216170B2 (en) 2005-02-25 2012-02-09 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof
JP4415896B2 (ja) * 2005-04-20 2010-02-17 トヨタ自動車株式会社 車両用空調装置
US8957070B2 (en) * 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
CN101573357B (zh) * 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
US20100183658A1 (en) * 2007-03-30 2010-07-22 The Brigham And Women's Hospital, Inc. Novel Compounds for Enhancing MHC Class II Therapies
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Ｍｃｌ-1 억제제
MX2009011210A (es) * 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.

Also Published As

Publication number Publication date
US9035047B2 (en) 2015-05-19
EP3243814A1 (en) 2017-11-15
AU2008242983A1 (en) 2008-10-30
US20140051683A1 (en) 2014-02-20
US20090054402A1 (en) 2009-02-26
ES2705599T3 (es) 2019-03-26
JP2014129399A (ja) 2014-07-10
WO2008131000A2 (en) 2008-10-30
KR101511074B1 (ko) 2015-04-13
BRPI0810365A2 (pt) 2014-10-29
MY162157A (en) 2017-05-31
JP5745661B2 (ja) 2015-07-08
US20150284328A1 (en) 2015-10-08
JP5496877B2 (ja) 2014-05-21
EP3243814B1 (en) 2018-10-17
NZ579833A (en) 2012-11-30
CN101743224A (zh) 2010-06-16
KR20090130137A (ko) 2009-12-17
WO2008131000A3 (en) 2008-12-18
EP2134684B1 (en) 2017-08-02
ES2643164T3 (es) 2017-11-21
CA2682356C (en) 2016-06-14
EP2134684A2 (en) 2009-12-23
US8445679B2 (en) 2013-05-21
ZA200906956B (en) 2011-03-30
AU2008242983B2 (en) 2013-07-11
CO6220947A2 (es) 2010-11-19
US9359296B2 (en) 2016-06-07
RU2009141986A (ru) 2011-05-27
CA2682356A1 (en) 2008-10-30
DOP2009000246A (es) 2009-11-15
MX2009011211A (es) 2009-10-30
JP2010524956A (ja) 2010-07-22
IL201432A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
DOP2009000246A (es) Indoles sustituidos en la posicion 7 inhibidores de mcl-1
NL301145I2 (nl) Tirbanibulin
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
CY1113975T1 (el) Παραγοντες για προληψη και θεραπεια διαταραχων που περιλαμβανουν διαφοροποιηση των υποδοχεων ryr
CY1115588T1 (el) Αναστολεις ανθρωπινης πρωτεϊνικης φωσφατασης τυροσινης-β και η φαρμακευτικη χρηση τους
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
MX2009011210A (es) Inhibidores de mcl1 de indol 7-no sustituido.
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
ECSP077836A (es) Compuestos mejorados farmacocinéticamente
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
ECSP099500A (es) Compuestos y composiciones como inhibidores de proteína quinasa
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
HN2009001112A (es) Inhibidores de la actividad de la akt
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
NO20080141L (no) Indanderivater som modulatorer av ionekanaler